免疫治疗时代的骨髓保留RT

Q4 Medicine

Nowotwory Pub Date : 2018-02-22 DOI:10.5603/NJO.2017.0050

Ł. Kuncman, Malwina Pietrzykowska-Kuncman, J. Danielska, Jolanta Łuniewska-Bury, J. Fijuth

{"title":"免疫治疗时代的骨髓保留RT","authors":"Ł. Kuncman, Malwina Pietrzykowska-Kuncman, J. Danielska, Jolanta Łuniewska-Bury, J. Fijuth","doi":"10.5603/NJO.2017.0050","DOIUrl":null,"url":null,"abstract":"Recent advances in the field of immunotherapy have changed the perception of cancer treatment to complex model with host immunity in the spotlight. Potential synergy of immunotherapy drugs [aiming cytotoxic T cell antigen 4 (CTLA-4) or programmed cell death-1/ligand (PD-1/PD-L1)] and radiotherapy (RT) have established basis for ongoing clinical trials testing combined treatment. It was shown that complete blood cell counts (CBC) parameters may correlate with cancer survival, toxicity and outcomes of treatment. Therefore, reduction of hematologic toxicity of cancer treatment may gain in significance. Modern dose delivery techniques compromise dose reduction in critical organs (like bone marrow — BM) with adequate irradiation of target volumes. In addition, usage of modern imaging like positron emission tomography (PET), magnetic resonance imaging (MRI) allows to divide the volume of BM to active and inactive one. In this review, we discuss the synergy of RT and immunity and techniques of Bone Marrow Sparing RT (BMS-RT).","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"25 1","pages":"301-307"},"PeriodicalIF":0.0000,"publicationDate":"2018-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Bone marrow sparing RT in era of immunotherapy\",\"authors\":\"Ł. Kuncman, Malwina Pietrzykowska-Kuncman, J. Danielska, Jolanta Łuniewska-Bury, J. Fijuth\",\"doi\":\"10.5603/NJO.2017.0050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recent advances in the field of immunotherapy have changed the perception of cancer treatment to complex model with host immunity in the spotlight. Potential synergy of immunotherapy drugs [aiming cytotoxic T cell antigen 4 (CTLA-4) or programmed cell death-1/ligand (PD-1/PD-L1)] and radiotherapy (RT) have established basis for ongoing clinical trials testing combined treatment. It was shown that complete blood cell counts (CBC) parameters may correlate with cancer survival, toxicity and outcomes of treatment. Therefore, reduction of hematologic toxicity of cancer treatment may gain in significance. Modern dose delivery techniques compromise dose reduction in critical organs (like bone marrow — BM) with adequate irradiation of target volumes. In addition, usage of modern imaging like positron emission tomography (PET), magnetic resonance imaging (MRI) allows to divide the volume of BM to active and inactive one. In this review, we discuss the synergy of RT and immunity and techniques of Bone Marrow Sparing RT (BMS-RT).\",\"PeriodicalId\":39938,\"journal\":{\"name\":\"Nowotwory\",\"volume\":\"25 1\",\"pages\":\"301-307\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-02-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nowotwory\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/NJO.2017.0050\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nowotwory","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/NJO.2017.0050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

摘要

近年来免疫治疗领域的进展使人们对癌症治疗的认识转变为宿主免疫的复杂模型。免疫治疗药物[针对细胞毒性T细胞抗原4 (CTLA-4)或程序性细胞死亡-1/配体(PD-1/PD-L1)]与放疗(RT)的潜在协同作用为正在进行的联合治疗的临床试验奠定了基础。研究表明，全血细胞计数(CBC)参数可能与癌症生存、毒性和治疗结果相关。因此，降低癌症治疗的血液学毒性可能具有重要意义。现代给药技术在靶体积足够照射的情况下降低了关键器官(如骨髓- BM)的剂量。此外，利用正电子发射断层扫描(PET)、磁共振成像(MRI)等现代成像技术，可以将BM的体积划分为活动体积和非活动体积。本文就骨髓保留放疗(BMS-RT)与免疫的协同作用及相关技术作一综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bone marrow sparing RT in era of immunotherapy

Recent advances in the field of immunotherapy have changed the perception of cancer treatment to complex model with host immunity in the spotlight. Potential synergy of immunotherapy drugs [aiming cytotoxic T cell antigen 4 (CTLA-4) or programmed cell death-1/ligand (PD-1/PD-L1)] and radiotherapy (RT) have established basis for ongoing clinical trials testing combined treatment. It was shown that complete blood cell counts (CBC) parameters may correlate with cancer survival, toxicity and outcomes of treatment. Therefore, reduction of hematologic toxicity of cancer treatment may gain in significance. Modern dose delivery techniques compromise dose reduction in critical organs (like bone marrow — BM) with adequate irradiation of target volumes. In addition, usage of modern imaging like positron emission tomography (PET), magnetic resonance imaging (MRI) allows to divide the volume of BM to active and inactive one. In this review, we discuss the synergy of RT and immunity and techniques of Bone Marrow Sparing RT (BMS-RT).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nowotwory Medicine-Oncology

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： NOWOTWORY Journal of Oncology publishes papers which cover all aspects of oncology but concentrates on clinical studies, both research orientated and treatment orientated, rather than on laboratory studies. Contributions are also welcomed from the fields of epidemiology, tumor pathology, radiobiology and radiation physics.